Frequency Therapeutics Begins Phase 2a Testing on Drug to Cure Hearing Loss

Frequency Therapeutics has commenced dosing in a Phase 2a clinical study of FX-322, a drug designed to regenerate auditory hair cells and restore hearing function. This multi-center, randomized, double-blind, placebo-controlled study aims to further establish the positive hearing signal observed in a Phase 1/2 study, including improved clarity of sound and word recognition. Frequency also hopes to evaluate safety and define the potential dosing regimen in this study expected to enroll 96 adults aged...

Audiology

Fri Oct 11, 2019 13:33

Topography of vibration frequency responses on the bony tympano-periotic complex of the pilot whale <em>Globicephala macrorhynchus</em>

Publication date: Available online 10 October 2019Source: Hearing ResearchAuthor(s): Itamar Tsur, Nir Shaviv, Israel Bronstein, David Elmakis, Oshri Knafo, Yehudah L. WernerAbstractIn modern Cetacea, the ear bone complex comprises the tympanic and periotic bones forming the tympano-periotic complex (TPC), differing from temporal bone complexes of other mammals in form, construction, position, and possibly function. To elucidate its functioning in sound transmission, we studied the vibration response...

Hearing Research

Fri Oct 11, 2019 17:05